FGFR2 gene amplifications, which result in receptor overexpression and constitutive oncogenic signalling independent of ligand binding, are the most common form of genetically-driven FGFR2 dysregulation in GC, occurring in 4–7% of all patients [24,25,26,27,28,29]. Here, FGFR2 is linked to gastric cancer.